Sign in

AGTC on NASDAQ

Applied Genetic Technologies Corporation

Logo: https://www.agtc.com/, Non-free logo, via Wikipedia5

Biotechnology company

The Applied Genetic Technologies Corporation was a publicly traded biotechnology company that is part of the NASDAQ Biotechnology Index. It was founded in 1999 and has its headquarters in Alachua, Florida. In late June 2019, the company announced the appointment of Global Clinical and Medical Affairs Veteran, Theresa G.H. Heah, M.D., M.B.A., to Join as Chief Medical Officer.3 Its shares trade on NASDAQ under the symbol AGTC.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

$325.0KRevenue, fiscal 20226
-$68.9MNet income, fiscal 20226
2001Founded1

Compare with BioAtla, Inhibikase Therapeutics, Inc. or Artiva Biotherapeutics, Inc., or pick any stock.

  • TickerAGTC on NASDAQ1
  • Industrybiotechnology1
  • HeadquartersAlachua1
  • Websitewww.agtc.com
  • Legal formDelaware corporation1
  • Incorporated inDE7
  • Business address14193 Nw 119Th Terrace, Suite #10, Alachua, Fl 326157
  • Filer categoryNon-accelerated filer, Smaller reporting company7
  • LEI549300I3X9WJZYN79L354
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O Corporation Service Company, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 37196954

See how the biggest companies compare on our leaderboards

The Applied Genetic Technologies Corporation was a publicly traded biotechnology company that is part of the NASDAQ Biotechnology Index. It was founded in 1999 and has its headquarters in Alachua, Florida. In late June 2019, the company announced the appointment of Global Clinical and Medical Affairs Veteran, Theresa G.H. Heah, M.D., M.B.A., to Join as Chief Medical Officer.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-20361.5%Operating margin6
-21213.2%Net margin6
-35.0%Revenue growth, 20226
-233.9%Return on equity6
0.31×Debt to equity6
-$67.4MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development95¢$49.5M
  • Interest5¢$2.7M

Out of $325.0K in revenue.6 The company lost money this year.

Financial statements

Revenue891011126$325.0K in 2022−86% since 2015
0$20.0M$40.0M$60.0M2015: $2.4M$2.4M20152016: $47.4M$47.4M2016+1912%2017: $39.5M$39.5M2017−17%2018: $24.2M$24.2M2018−39%2019: $41.7M$41.7M2019+72%2020: $2.5M$2.5M2020−94%2021: $500.0K$500.0K2021−80%2022: $325.0K$325.0K2022−35%
Operating income891011126-$66.2M in 2022+170% since 2015
-$80.0M-$60.0M-$40.0M-$20.0M0$20.0M2015: -$24.5M-$24.5M20152016: -$2.1M-$2.1M2016−91%2017: $1.9M$1.9M20172018: -$22.4M-$22.4M20182019: -$4.3M-$4.3M2019−81%2020: -$46.9M-$46.9M2020+979%2021: -$58.5M-$58.5M2021+25%2022: -$66.2M-$66.2M2022+13%
Net income891011126-$68.9M in 2022+184% since 2015
-$80.0M-$60.0M-$40.0M-$20.0M0$20.0M2015: -$24.3M-$24.3M20152016: -$1.4M-$1.4M2016−94%2017: $407.0K$407.0K20172018: -$21.3M-$21.3M20182019: -$2.0M-$2.0M2019−91%2020: -$45.9M-$45.9M2020+2188%2021: -$57.8M-$57.8M2021+26%2022: -$68.9M-$68.9M2022+19%
Fiscal year20152016201720182019202020212022
Revenue$2.4M8$47.4M9$39.5M9$24.2M10$41.7M11$2.5M12$500.0K6$325.0K6
Research and development$18.1M8$39.4M9$26.2M9$32.2M10$33.2M11$35.8M12$44.4M6$49.5M6
Operating expenses$66.5M6
Operating income-$24.5M8-$2.1M9$1.9M9-$22.4M10-$4.3M11-$46.9M12-$58.5M6-$66.2M6
Interest$11.0K12$1.5M6$2.7M6
Income before tax-$68.8M6
Income tax$2.4M9$72.0K10$76.0K11$83.0K12-$2.1M6$06
Net income-$24.3M8-$1.4M9$407.0K9-$21.3M10-$2.0M11-$45.9M12-$57.8M6-$68.9M6
Earnings per share-$1.508-$0.089$0.029-$1.1810-$0.1111-$2.1712-$1.776-$1.536
Earnings per share (diluted)-$1.508-$0.089$0.029-$1.1810-$0.1111-$2.1712-$1.776-$1.536
Shares (weighted, basic)45.0M shares6
Shares (weighted, diluted)45.0M shares6

Compare Applied Genetic Technologies Corporation with another company

Corporate structure

Applied Genetic Technologies Corporation sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Applied Genetic Technologies Corporation

  • Applied Genetic Technologies Corporation Alachua, Florida, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Applied Genetic Technologies Corporation reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$11.9M6 Jun 30, 2022$10.5M6 Jun 30, 2021+12.6%
Accumulated depreciation$7.2M6 Jun 30, 2022$5.9M6 Jun 30, 2021+21.6%
Property and equipment, net$4.7M6 Jun 30, 2022$4.7M6 Jun 30, 2021+1.2%
Finance-lease assets$34.0K6 Jun 30, 2021$80.0K12 Jun 30, 2020−57.5%
Operating-lease assets (leased space)$3.0M6 Jun 30, 2022$3.2M6 Jun 30, 2021−3.9%

Real estate and locations

ItemLatestA year beforeChange
Area of land21,250 sq ft6 May 13, 2021

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$46.4M6 Jun 30, 2022$105.1M6 Jun 30, 2021−55.9%
Marketable securities, current$2.0M6 Jun 30, 2021$42.0M12 Jun 30, 2020−95.2%
Stakes in other companies (equity method)$7.8M6 Jun 30, 2022$8.0M6 Jun 30, 2021−2.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$1.4M6 Jun 30, 2022$1.3M6 Jun 30, 2021+11.3%
Finite-lived intangibles, gross$3.7M6 Jun 30, 2022$3.4M6 Jun 30, 2021+9.9%
Accumulated amortization$2.3M6 Jun 30, 2022$2.1M6 Jun 30, 2021+9.0%
Finite-lived intangibles, net$1.4M6 Jun 30, 2022$1.3M12 Jun 30, 2021+11.6%

Leadership

Who has led Applied Genetic Technologies Corporation, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Susan B. Washer2014–2022

President

  1. Susan B. Washer2014–2022

Chief financial officer

  1. Lawrence E. Bullock2014–2017
  2. William A. Sullivan2017–2020
  3. Jonathan I. Lieber2021–2022
20052010201520202025
Board members and other officers (28)

Timeline

  1. Dec 1, 20228-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer49
  2. Nov 29, 20228-K Other events50
  3. Nov 23, 20228-K Other events51
  4. Oct 24, 20228-K Entered a material agreement; Bylaws or fiscal year changed; Other events52
  5. Aug 26, 20228-K Executive or director change53
  6. Aug 12, 20228-K Executive or director change54
  7. Jul 14, 20228-K Entered a material agreement; Other events55
  8. Jun 10, 20228-K Listing notice or transfer56
  9. May 16, 20228-K Regulation FD disclosure57
  10. May 9, 20228-K Entered a material agreement58
  11. Mar 23, 20228-K Entered a material agreement; Other events59
  12. Mar 2, 20228-K Executive or director change60
  13. Mar 27, 2014Went public Listed on NASDAQ1
  14. Mar 26, 2014New chief executive Susan B. Washer becomes CEO18
  15. 2001Founded Founded1

Calendar

When it reported results

  1. Feb 14, 2022Reported quarterly or annual results61
  2. Nov 9, 2021Reported quarterly or annual results62

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

108 filings to the SEC since October 2021: 2 annual reports, 4 quarterly reports, 19 major events, 40 insider forms, 8 large holders, 35 other. The latest 20:

  1. Feb 14, 2023SC 13G/A EDGAR
  2. Dec 12, 202215-12G EDGAR
  3. Dec 8, 2022SC 13D APPLIED GENETIC TECHNOLOGIES CORPORATION EDGAR
  4. Dec 6, 2022EFFECT EDGAR
  5. Dec 6, 2022EFFECT EDGAR
  6. Dec 6, 2022EFFECT EDGAR
  7. Dec 1, 202225-NSE EDGAR
  8. Dec 1, 2022S-8 POS EDGAR
  9. Dec 1, 2022S-8 POS EDGAR
  10. Dec 1, 2022S-8 POS EDGAR
  11. Dec 1, 2022S-8 POS EDGAR
  12. Dec 1, 2022S-8 POS EDGAR
  13. Dec 1, 2022POS AM EDGAR
  14. Dec 1, 2022POS AM EDGAR
  15. Dec 1, 2022POS AM EDGAR
  16. Dec 1, 20228-K EDGAR
  17. Dec 1, 2022SC 14D9/A EDGAR
  18. Dec 1, 2022SC TO-T/A EDGAR
  19. Dec 1, 20224 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  20. Dec 1, 20224 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR

The 108 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 0 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 1, 2022Potter Stephen WChief Business OfficerSale8,070$0.77$6.2KForm 4
May 27, 2022Reynolds Gerald AnthonyChief Accounting OfficerSale3,994$0.85$3.4KForm 4
Feb 18, 2022Washer Susan B.President and CEOSale9,950$2.18$21.7KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Applied Genetic Technologies Corporation is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAPPLIED GENETIC TECHNOLOGIES CORP2
  • CIK0001273636
  • Employer ID (EIN)59-35537102
  • Filer statusNon-accelerated filer<br>smaller reporting company2
  • Incorporated inDelaware2
  • Fiscal year endsJune 302
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)2
  • Business address14193 Nw 119Th Terrace, Suite #10, Alachua, FL 326152
  • Phone386-462-22042
  • Shares outstanding67,632,195 as of Nov 16, 202214
  • Public float$81.3M as of Dec 31, 202117
  • On EDGAR sinceDec 16, 20032
  • Filings569 in all: 4 (191), 8-K (105), 3 (36), SC 13G/A (36), 10-Q (26), SC 13G (21), CORRESP (14), 4/A (13)2
    All 48 form types

    10-K (9), EFFECT (9), DEF 14A (8), UPLOAD (8), 424B5 (7), SC 14D9/A (7), 10-K/A (6), SC 13D/A (6), CT ORDER (5), S-8 (5), S-8 POS (5), S-1/A (4), 424B4 (3), 8-K/A (3), POS AM (3), REGDEX/A (3), S-1 (3), S-3 (3), SC 13D (3), SC TO-T/A (3), 5 (2), D (2), DEFA14A (2), REGDEX (2), 10-Q/A (1), 15-12G (1), 25-NSE (1), 3/A (1), 8-A12B (1), CERTNAS (1), D/A (1), DRS (1), DRS/A (1), NT 10-Q (1), POS EX (1), S-3/A (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Sep 27, 2022
    Quarterly report (10-Q) Nov 21, 2022
    Proxy statement (DEF 14A) Oct 15, 2021
    Latest 8-K (8-K) Dec 1, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
    SEC EDGAROther events
  51. 51
    SEC EDGAROther events
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68